{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=fluzone&page=23",
    "query": {
      "intervention": "fluzone",
      "page": 23
    },
    "page_size": 10
  },
  "pagination": {
    "page": 23,
    "page_size": 10,
    "total_count": 1164,
    "total_pages": 117,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=fluzone&page=24&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=fluzone&page=22&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T21:23:47.489Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01756950",
      "title": "Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "2 mg/kg CR8020",
          "type": "BIOLOGICAL"
        },
        {
          "name": "5 mg/kg CR8020",
          "type": "BIOLOGICAL"
        },
        {
          "name": "15 mg/kg CR8020",
          "type": "BIOLOGICAL"
        },
        {
          "name": "30 mg/kg CR8020",
          "type": "BIOLOGICAL"
        },
        {
          "name": "50 mg/kg CR8020",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Crucell Holland BV",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 64,
      "start_date": "2013-01",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2013-12-19",
      "last_synced_at": "2026-11-19T21:23:47.489Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01756950"
    },
    {
      "nct_id": "NCT03283319",
      "title": "Panblok H7 Vaccine Adjuvanted With AS03 or MF59",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza, Human"
      ],
      "interventions": [
        {
          "name": "3.75 ug Panblok H7",
          "type": "BIOLOGICAL"
        },
        {
          "name": "7.5 ug Panblok H7",
          "type": "BIOLOGICAL"
        },
        {
          "name": "15 ug Panblok H7",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AS03",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Biomedical Advanced Research and Development Authority",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 366,
      "start_date": "2017-09-20",
      "completion_date": "2018-11-09",
      "has_results": true,
      "last_update_posted_date": "2020-05-06",
      "last_synced_at": "2026-11-19T21:23:47.489Z",
      "location_count": 4,
      "location_summary": "Lenexa, Kansas • Wichita, Kansas • Lexington, Kentucky + 1 more",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03283319"
    },
    {
      "nct_id": "NCT00380211",
      "title": "Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Influenza vaccine (A/H3N2, A/H1N1, and B strains)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluarix",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 660,
      "start_date": "2006-09",
      "completion_date": "2006-11",
      "has_results": false,
      "last_update_posted_date": "2016-10-07",
      "last_synced_at": "2026-11-19T21:23:47.489Z",
      "location_count": 6,
      "location_summary": "Miami, Florida • Lenexa, Kansas • Binghamton, New York + 3 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Binghamton",
          "state": "New York"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00380211"
    },
    {
      "nct_id": "NCT00377611",
      "title": "Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Fluarix™",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 3054,
      "start_date": "2006-10-05",
      "completion_date": "2007-06-20",
      "has_results": true,
      "last_update_posted_date": "2018-10-09",
      "last_synced_at": "2026-11-19T21:23:47.489Z",
      "location_count": 9,
      "location_summary": "Mobile, Alabama • Delray Beach, Florida • Pembroke Pines, Florida + 6 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Delray Beach",
          "state": "Florida"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Somers Point",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00377611"
    },
    {
      "nct_id": "NCT03629184",
      "title": "Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Baloxavir Marboxil",
          "type": "DRUG"
        },
        {
          "name": "Oseltamivir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "1 Year to 11 Years"
      },
      "enrollment_count": 173,
      "start_date": "2018-11-20",
      "completion_date": "2019-04-03",
      "has_results": true,
      "last_update_posted_date": "2020-04-29",
      "last_synced_at": "2026-11-19T21:23:47.489Z",
      "location_count": 27,
      "location_summary": "Birmingham, Alabama • Harrisburg, Arkansas • Jonesboro, Arkansas + 22 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Harrisburg",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Ontario",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03629184"
    },
    {
      "nct_id": "NCT00001127",
      "title": "Study of a Flu Vaccine in Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Influenza virus vaccine (CAIV-T)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "18 Months to 18 Years"
      },
      "enrollment_count": 15000,
      "start_date": null,
      "completion_date": "2005-11",
      "has_results": false,
      "last_update_posted_date": "2010-08-27",
      "last_synced_at": "2026-11-19T21:23:47.489Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001127"
    },
    {
      "nct_id": "NCT03328325",
      "title": "Age and Response to Flu Vaccines",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Influenza",
        "Influenza Immunisation"
      ],
      "interventions": [
        {
          "name": "Influenza Virus Quadrivalent Inactivated Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "9 Years to 99 Years"
      },
      "enrollment_count": 152,
      "start_date": "2017-12-14",
      "completion_date": "2020-04-20",
      "has_results": true,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-11-19T21:23:47.489Z",
      "location_count": 2,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03328325"
    },
    {
      "nct_id": "NCT00524940",
      "title": "Trial to Describe the Safety and Immunogenicity of Fluzone®",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Inactivated, Split-Virion Influenza Virus",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 124,
      "start_date": "2007-08",
      "completion_date": "2007-12",
      "has_results": true,
      "last_update_posted_date": "2016-04-14",
      "last_synced_at": "2026-11-19T21:23:47.489Z",
      "location_count": 1,
      "location_summary": "Norfolk, Virginia",
      "locations": [
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00524940"
    },
    {
      "nct_id": "NCT02242643",
      "title": "Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "FluLaval™ Quadrivalent",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluzone® Quadrivalent",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "35 Months",
        "sex": "ALL",
        "summary": "6 Months to 35 Months"
      },
      "enrollment_count": 2432,
      "start_date": "2014-10-01",
      "completion_date": "2015-06-23",
      "has_results": true,
      "last_update_posted_date": "2018-09-07",
      "last_synced_at": "2026-11-19T21:23:47.489Z",
      "location_count": 64,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Tucson, Arizona + 56 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02242643"
    },
    {
      "nct_id": "NCT01059617",
      "title": "Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "GSK Biologicals' FluLaval®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (saline)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "19 Years to 40 Years"
      },
      "enrollment_count": 133,
      "start_date": "2010-02-09",
      "completion_date": "2011-10-21",
      "has_results": true,
      "last_update_posted_date": "2018-08-20",
      "last_synced_at": "2026-11-19T21:23:47.489Z",
      "location_count": 3,
      "location_summary": "Milford, Massachusetts • Salisbury, North Carolina • Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Milford",
          "state": "Massachusetts"
        },
        {
          "city": "Salisbury",
          "state": "North Carolina"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01059617"
    }
  ]
}